About This Calculator

The Reclast (zoledronic acid) Dosing Calculator is designed for healthcare professionals to assess patient eligibility for treatment based on renal function. It calculates creatinine clearance (CrCl) using the Cockcroft-Gault formula, which is a critical step before administering zoledronic acid to prevent potential renal toxicity.

Interpretation of Outputs

The calculator provides a clear recommendation based on the calculated CrCl value:

• Eligible for Reclast: This result is generated when the calculated CrCl is 35 mL/min or greater. The standard dose for the selected indication is recommended.
• Reclast is Contraindicated: This result is generated when the calculated CrCl is less than 35 mL/min. Administration of Reclast is contraindicated due to the increased risk of acute renal failure.

How to Use the Calculator

To determine a patient's eligibility, enter the following clinical data into the corresponding fields:

• Indication for Use: Select the appropriate FDA-approved indication from the dropdown list.
• Age: Enter the patient's age in years.
• Weight: Input the patient's body weight and select the unit (kg or lb).
• Sex: Select the patient's biological sex, as this is a factor in the Cockcroft-Gault equation.
• Serum Creatinine (SCr): Enter the patient's most recent serum creatinine value and select the unit (mg/dL or µmol/L).

After all fields are completed, the "Calculate" button will become active.

Dosing Overview

For all approved indications in patients with adequate renal function (CrCl ≥ 35 mL/min), the recommended dose of Reclast is a 5 mg intravenous (IV) infusion administered over no less than 15 minutes. The frequency of administration depends on the indication:

• Osteoporosis (Treatment and Prevention): Once yearly.
• Paget's Disease of Bone: A single 5 mg infusion.

Patients must be adequately hydrated before administration and supplemented with daily calcium and vitamin D.

Switching to Reclast

When transitioning a patient to Reclast from another bisphosphonate, clinical judgment is required. For patients on oral bisphosphonates, Reclast can be initiated after an appropriate washout period. For patients switching from another intravenous bisphosphonate, Reclast should generally be administered when the next dose of the previous agent would have been due.

Missed Dose

If a yearly dose of Reclast for osteoporosis is missed, the infusion should be administered as soon as it can be rescheduled. The next annual dose should then be scheduled approximately 12 months from the date of this most recent infusion. Do not administer two doses in close proximity.

Safety Alerts

• Renal Impairment: Reclast is contraindicated in patients with a CrCl <35 mL/min. Renal function must be assessed prior to each dose.
• Hypocalcemia: Pre-existing hypocalcemia must be corrected before initiating Reclast. Monitor serum calcium levels, especially in patients with Paget's disease or hypoparathyroidism.
• Osteonecrosis of the Jaw (ONJ): ONJ has been reported with bisphosphonate use. A routine oral examination should be performed by the prescriber prior to initiation, and patients should be advised to practice good oral hygiene.
• Atypical Femur Fractures: Atypical, low-trauma fractures of the femoral shaft have been reported. Patients presenting with thigh or groin pain should be evaluated to rule out an incomplete femur fracture.

Frequently Asked Questions (FAQ)

1. What formula does this calculator use to determine creatinine clearance?
The calculator uses the standard Cockcroft-Gault equation, which is specified in the Reclast prescribing information for renal function assessment.

2. Why is CrCl of 35 mL/min the cutoff for Reclast?
This threshold was established in clinical trials and is recommended by the manufacturer to minimize the risk of significant renal adverse events, including acute renal failure.

3. Can I use this tool for patients with unstable renal function?
No. The Cockcroft-Gault formula assumes stable renal function. This calculator is not intended for use in patients with acute kidney injury or rapidly changing serum creatinine levels.

4. Does body weight impact the CrCl calculation?
Yes, actual body weight is a key variable in the Cockcroft-Gault formula. The calculator uses the weight you enter to compute the CrCl.

5. Can this calculator be used for pediatric patients?
No. Reclast is not indicated for use in children, and this calculator is designed for adults aged 18 and older.

6. Does the indication for use change the CrCl threshold?
No, the contraindication of CrCl <35 mL/min applies to all approved indications for Reclast.

7. What pre-infusion steps are essential besides checking CrCl?
Ensure the patient is adequately hydrated, rule out hypocalcemia with a recent serum calcium level, and assess for risk factors for ONJ.

8. Why is there no option for race in the calculator?
The Cockcroft-Gault equation does not include a variable for race. Other equations, such as MDRD or CKD-EPI, do include race but are not the formula specified for Reclast dosing.

9. What should I do if a patient's CrCl is borderline, such as 36 mL/min?
While technically eligible, use clinical judgment. Consider the stability of their renal function, comorbidities, and concomitant nephrotoxic medications before proceeding with the infusion.

References

1. RECLAST® (zoledronic acid) injection Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2023. View PDF
2. Novartis US. Reclast® (zoledronic acid) Official HCP Site. hcp.novartis.com
3. Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis-2020 Update. Endocr Pract. 2020;26(Suppl 1):1-46. View Guideline
4. Eastell R, Rosen CJ, Black DM, Cheung AM, Murad MH, Shoback D. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2019;104(5):1595-1622. View Guideline